BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating
On March 2, 2026, BTIG raised the price target on Opus Genetics, Inc. (NASDAQ:IRD) to $12 from $7 and maintained a Buy rating.
Opus Genetics Inc. (IRD)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 4,781,330 | $9,610,473 | +43% | 0.32% |
| 2. | Perceptive Advisors Joseph Edelman | 4,325,000 | $8,693,250 | 0.15% | |
| 3. | Balyasny Asset Management Dmitry Balyasny | 2,718,029 | $5,463,238 | 0.01% | |
| 4. | Millennium Management Israel Englander | 2,002,550 | $4,025,125 | 0% | |
| 5. | Opaleye Management James A. Silverman | 1,120,000 | $2,251,200 | +2% | 0.3% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.97 | 83,000 | $163,418.70 | 83,000 | 2025-12-29 | Filing | |
| $1.98 | 81,000 | $160,274.70 | 1,891,430 | 2025-12-29 | Filing | |
| $0.98 | 100,000 | $97,600.00 | 599,150 | 2024-12-26 | Filing | |
| $0.98 | 10,000 | $9,834.00 | 342,800 | 2024-11-21 | Filing | |
| $1.02 | 9,706 | $9,942.83 | 492,950 | 2024-11-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.25 | 3,719 | $19,525.12 | 300,781 | 2026-03-16 | Filing | |
| $5.25 | 2,816 | $14,769.92 | 190,312 | 2026-03-16 | Filing | |
| $5.21 | 24,438 | $127,326.87 | 1,750,855 | 2026-03-16 | Filing | |
| $5.12 | 3,719 | $19,046.11 | 516,775 | 2026-03-16 | Filing | |
| $2.15 | 4,000,000 | $8,600,000.00 | 5,492,171 | 2025-12-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,683,429 | $7,403,692 | 8.96% | |
| 2. | 2,322,897 | $4,669,022 | 0% | |
| 3. | 1,665,631 | $3,347,918 | 2.12% | |
| 4. | 736,842 | $1,481,052 | 0.26% | |
| 5. | 504,983 | $1,015,726 | 0% |
News See All
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT
On November 25, 2025, The Fly reported that Piper Sandler initiated coverage of Opus Genetics, Inc. (NASDAQ:IRD) with an “Overweight” rating and a $7 price target.
12 Hot Penny Stocks to Invest in Right Now
Goldman Sachs Asset Management portfolio manager Greg Tuorto appeared on CNBC on November 17, 2025.
Hedge Fund Resource Center